 COPENHAGEN, Denmark, Sept. 06, 2021 GLOBE NEWSWIRE -- Forward Pharma AS NASDAQ:FWP we, Forward or the Company, today announced that the Technical Board of Appeal the TBA of the European Patent Office the EPO has dismissed Forwards appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent the 355 patent following the oral hearing. 